The biological profile of the new bioconjugates after labeling with In-111 was evaluated in direct comparison with [111In]In-AU-RM26-M1 in GRPR-expressing prostate adenocarcinoma PC-3 cells [30] and mice models, and their potential discussed as radiotherapeutic candidates in prostate cancer after labeling with particle emitting radiometals, like Lu-177. This evidence concerns the gene GRPR and prostate carcinoma.